| Sources: Company Website. Company Presentation. -----
As mentioned above, SXTP has several key potential catalysts to watch for at this moment. Take a look here:
No. 1 SXTP Potential Catalysts - A Tiny Float Could Create A Volatile Situation (In Moments...).
According to info from the Yahoo Finance website, SXTP has an extremely low float.
In fact, the website reports this profile to have approx. 1.5Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
Could more positive company news early in 2025 provide a near term spark? -----
No. 2 SXTP Potential Catalysts - The CEO Appears To Be Bullish On SXTP With Recent Acquisition(s).
In December of 2024, Geoffrey Dow, the Chief Economic Officer (CEO) of 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP), made multiple share purchases of 17k shares or more of the company's st-ock.
This move may catch the attention of market analysts as insider buying often signals confidence in the company's future prospects.
Dow is a 20-year veteran in tropical disease product development, having spearheaded the regulatory approval of ARAKODA®.
Check out the full Form 4 here. -----
No. 3 SXTP Potential Catalysts - A Game-Changing Patent License Agreement With Tufts Med Center Centers Around Key Collab.
Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
WASHINGTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
Tafenoquine is not currently approved by the U.S. Food and Drug Administration (“FDA”) for the treatment and prevention of babesiosis.
The agreement follows initiation of collaboration between researchers from both organizations to study the activity of tafenoquine against babesiosis, a serious tick-borne disease caused by microscopic parasites that infect red blood cells. The study formed the basis of U.S. Provisional Patent Application No. 63/461,060, and related U.S. utility and PCT applications, granting the parties shared intellectual property rights to tafenoquine’s potential future use for babesiosis.
...
“This agreement demonstrates the growing confidence Tufts Medical Center and 60 Degrees Pharmaceuticals have in tafenoquine’s potential as a next-generation therapeutic for babesiosis,” said Chief Executive Officer of 60 Degrees Pharmaceuticals, Inc., Geoff Dow, PhD. “Today, those whose disease has progressed past the initial stages of mild symptoms may have limited treatment options. We believe tafenoquine, if approved, has the potential to meet this growing unmet need. Tafenoquine also has the potential to become the first prophylaxis available for babesiosis.”
Read the full article here. -----
No. 4 SXTP Potential Catalysts - An Important Collab With Brigham And Women's Hospital Aims To Help Enrollment For Tafenoquine Trial.
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
WASHINGTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (60 Degrees Pharmaceuticals or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has entered into a clinical trial agreement with Brigham and Women’s Hospital (BWH) in Boston to conduct a double-blind, placebo-controlled study evaluating the safety and efficacy of tafenoquine in combination with standard of care treatment for hospitalized babesiosis patients.
The study, a randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients is also underway at Tufts Medical Center in Boston, Yale University, and Rhode Island Hospital, and is sponsored by 60 Degrees Pharmaceuticals. The two main study endpoints will be the time to sustained clinical resolution of symptoms and the time to molecular cure as determined by nucleic acid test (NAT) approved by the U.S. Food and Drug Administration (FDA).
At least 24, and as many as 33 patients, will be recruited in the summer of 2025, with an interim analysis anticipated early in 2026. The interim analysis will include both a test of significance, and size re-estimation to allow additional recruitment if required.
“We are pleased to be collaborating with Brigham and Women’s Hospital on finding answers to the question of how to bring a safe and effective new treatment option to people hospitalized with severe babesiosis, a potentially life-threatening tick-borne illness,” said Geoffrey Dow, PhD, chief executive officer and president of 60 Degrees Pharmaceuticals. “In the near term, this collaboration promises to substantially enhance our ability to complete enrollment of this important clinical trial during the 2025 tick season. We look forward to a productive collaboration with the Hospital.”
...
Read the full article here. -----
No. 5 SXTP Potential Catalysts - An Analyst Target Suggests Approximately Triple-Digit Potential Upside From Tuesday Afternoon Valuation.
As of the closing bell on Tuesday, an Ascendiant Capital Markets analyst target of $3.40 was suggesting serious upside potential.
In fact, there may be a growth potential of over 150% to that target from its closing valuation Tuesday!
Here's some highlights from the report:
- Babesiosis trial proceeding apace: SXTP previously announced it has signed clinical trial agreements with Yale, Tufts, and Rhode Island Hospital to carry out the study of Tafenoquine to treat Babesiosis. The trial is expected to recruit between 24 to 33 patients before an interim analysis is conducted, with sufficient enrollment capacity planned to ensure all subjects are recruited before the end of the 2025 tick season. If all goes well, the company will file an NDA by Q2 of FY26. In related news, the company announced IRB approval for a clinical study of Tafenoquine for Babesiosis in immunocompromised patients with persistent Babesia microti. The goal of the study is to confirm findings of a Yale study which showed an 80% cure rate in immunocompromised patients given weekly doses of Tafenoquine.
- Company continues to develop go-to-market strategy for ARAKODA for Malaria: With its second indication (ARAKODA for Babesiosis) currently in phase II clinical trials, the company’s primary revenue opportunity at the moment remains ARAKODA as a Malaria prophylactic. To wit, the company announced a 9-month marketing pilot with prescribing physicians designed to raise awareness of ARAKODA, as well as collect patient data which will assist in further US market expansion. The company is highlighting the fact that ARAKODA is the only new antimalarial in over a decade and is differentiated by broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile
-----
Coverage is officially reinitiated on 60 Degrees Pharmaceuticals, Inc. (Nasdaq: SXTP).
I'll be in touch with updates as the week moves forward. Talk again soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired by TD Media LLC for a period beginning on 12/10/2024 and ending on 12/11/2024 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”) to disseminate information about (SXTP:US) via digital communications.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired by TD Media LLC for a period beginning on 01/07/2025 and ending on 01/10/2025 to publicly disseminate information about (SXTP:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”) to disseminate information about (SXTP:US) via digital communications.
Neither SWN Media LLC or its member own shares of (SXTP:US).
Please see important disclosure information here: www.stockwirenews.net/disclosure
A member of SWN Media LLC is also a member of TD Media LLC.
Pursuant to an agreement between TD Media LLC and 60 Degrees Pharmaceuticals Inc., TD Media LLC has been hired for a period beginning on 01/07/2025 and ending on 01/10/2025 to publicly disseminate information about (SXTP:US) via digital communications. To date, including under the previously described agreement, TD Media LLC has been paid one hundred forty-nine thousand USD (“Funds”).These Funds were part of the funds that TD Media LLC received from 60 Degrees Pharmaceuticals Inc., the issuer of (SXTP:US).
Neither TD Media LLC or its member owns shares of (SXTP:US).
Please see important disclosure information here: https://lifewatermedia.com/disclosure/sxtp/ | 
No comments:
Post a Comment